Login
$KRYS
$297.90 -$7.33 (2.4%) Live

$KRYS SEC Filings

Filed On Filing
13 Nov 2026 Form 4: Rossi Dino A, Director

Gave 3,500 shares as a gift

02 Nov 2026 8-K: Results of Operations and Financial Condition

$127.3 million in 3Q VYJUVEK global revenue and $1.1 billion since launch

02 Nov 2026 10-Q
30 Oct 2026 SCHEDULE 13G/A
27 Oct 2026 SCHEDULE 13G/A
15 Oct 2026 8-K: Regulation FD Disclosure

Over 80% of assessed basal cell carcinoma lesions regressed across three Gorlin syndrome patients treated with KB113

16 Sep 2026 Form 4: Rossi Dino A, Director

Granted 1,187 Stock Option (Right to Buy) · Granted 471 Restricted Stock Units

16 Sep 2026 Form 4: Sutherland Everett Rand, Director

Granted 1,187 Stock Option (Right to Buy) · Granted 471 Restricted Stock Units

16 Sep 2026 Form 4: Mazzacco Catherine, Director

Granted 1,187 Stock Option (Right to Buy) · Granted 471 Restricted Stock Units

16 Sep 2026 Form 4: Mason Christopher, Director

Granted 1,187 Stock Option (Right to Buy) · Granted 471 Restricted Stock Units

16 Sep 2026 Form 4: Janney Daniel, Director

Granted 1,187 Stock Option (Right to Buy) · Granted 471 Restricted Stock Award

16 Sep 2026 Form 4: Gangolli Julian S, Director

Granted 1,187 Stock Option (Right to Buy) · Granted 471 Restricted Stock Units

04 Sep 2026 Form 4: Krishnan Suma, Director

Sold 25,000 shares ($8.98M)

04 Sep 2026 Form 4: Krishnan Krish S, Director

Sold 25,000 shares ($8.98M)

04 Sep 2026 144
04 Sep 2026 144
14 Aug 2026 Form 4: Rossi Dino A, Director

Gave 3,691 shares as a gift · Sold 25,000 shares ($8.23M)

14 Aug 2026 144
03 Aug 2026 8-K: Results of Operations and Financial Condition

$119.2 million in 2Q VYJUVEK global revenue and $965.9 million since launch

03 Aug 2026 10-Q

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support